The aim: to conduct a comparative analysis of the dynamics of health expenditures from GDP, cash expenditures of families and public expenditures on health in Ukraine, Poland and the countries of the WHO European Region. Materials and methods. The object of the research was the data of the WHO European Office. Historical, analytical-comparative, systemic, logical, graphic, mathematical-statistical and other research methods were used. Research results. It was found that all indicators of the analysis in Ukraine had an unstable character of changes in the years dynamics. Since 1995, Poland and European countries have seen a systematic increase in total health spending (%) of the country's GDP. The indicator of out-of-pocket expenses of families on medical and pharmaceutical support in Ukraine was significantly higher than in Poland and European countries, and its average values ​​in Ukraine were 1.5 times higher than in Poland. In 2014, this indicator reached its maximum (46.2 %) against the background of an increase in government spending (%) of total health spending (from 11.9 % to 12.7 %). In 2014, this indicator exceeded similar values ​​in Poland by 2.0 times and 1.7 times in European countries. In contrast, in Poland, the out-of-pocket expenses of families on medical and pharmaceutical support have been steadily decreasing from 30.0 % to 22.1 %, and since 2010 they have been lower than in European countries. According to government spending as a percentage of total health spending in Europe and Poland, there was a trend towards a gradual increase from 11.0 % to 13.2 % (European countries) and from 8.2 % to 10.7 % (Poland). The corresponding Ukrainian data were higher than in Poland and lower than in European countries (from 10.8 % to 11.4 %). Against the background of the unstable nature of the dynamics of changes in indicators characterizing the participation of the state in financing health care in Ukraine, since 2005, there has been an increase in the cash expenditures of Ukrainian families for relevant needs. As a result of systemic transformations in Poland, on the threshold of its accession to the EU (May 1, 2004), since 2005, there has been a decrease in the out-of-pocket expenditures of families against the background of a slight increase in % of public spending on health care. Conclusions. The unstable nature of the dynamics of changes in domestic indicators, in comparison with similar data that was observed in Poland and the countries of the WHO European Region, suggests the need to introduce more decisive actions, which should lead to a reformatting of the role of the state in financing the health system

Aim. To analyze medical prescriptions and the structure of the drug consumption in patients with lymphogranulomatosis in Ukraine. Materials and methods. The data of medical records (455) of patients with lymphogranulomatosis were studied. The historical, analytical-comparative, systemic, logical, hypothetical-deductive, graphical methods of scientific research, as well as clinical and economic analysis as one of the components of health technology assessment were used. Results. It was found that, on average, the patients were in the hospital for 32 bed-days, and they received 16,835 medical prescriptions. There were 37 prescriptions per patient. The leaders in the number of prescriptions were drugs from groups L – Antineoplastic and immunomodulating agents, B – Drugs affecting the blood system and hematopoiesis, and A – Drugs affecting the digestive system and metabolism. These groups of drugs accounted for more than half of medical prescriptions (9247 or 54.93 %). The structure of prescriptions was dominated by drugs in the form of solutions or powders for their preparation (62.78 % of all prescriptions or 10569). In accordance with the II level of the ATC classification, the first three positions in the number of prescriptions were drugs used in the chemotherapy and elimination of symptoms of exacerbation of chronic pathologies. These drugs were from the following groups: L01 – Antineoplastic and immunomodulating agents (12.80 % or 2154 prescriptions), B05 – Blood substitutes and perfusion solutions (11.95 % or 2012, respectively), C01 – Drugs for the treatment of heart diseases (9.99 % or 1681, respectively). Antineoplastic prescriptions ranged from 31 (L01C D01 – Paclitaxel) to 289 (L01DB01 – Doxorubicin) ones. The most prescribed drugs were L01DB01 – Doxorubicin, AA01 – Cyclophosphamide, and L01CB01 – Etoposide. It was proven that patients with lymphogranulomatosis received an average of 8.3 prescriptions of antitumor drugs. The general indicator of the drug consumption was 23440.30 thousand UAH or 822.58 thousand US dollars, which, in terms of one patient, amounted to 51,517.14 UAH or 1807.86 US dollars. It was found that 38797,60 UAH or 1361.50 USD were spent on the effective chemotherapy and maintenance of the patient’s body, which was 8.21 and 17.1 times more than the minimum wage and living wage according to the data presented in the state budget for 2020 in Ukraine. Conclusions. It has been found that medical prescriptions and the consumption of drugs by patients with lymphogranulomatosis reflect the nature of the therapy, namely the need for intensive courses of chemotherapy, polymorbidity of patients, as well as the severity of the pathological process. Considering the high cost of the treatment the solution to the issue of increasing the level of its availability requires a systemic solution in various directions. Key words: clinical and economic analysis; medical prescriptions; lymphogranulomatosis; Hodgkin’s disease; antineoplastic drugs; health technology assessment.